BiostockSynAct Pharma Completes Recruitment for ADVANCE
SynAct Pharma has met the recruitment target for its Phase II ADVANCE study of resomelagon. Once the final patient completes the 12-week period and follow-up, database lock will commence at over 30 clinics. The trial evaluates dose-dependent safety and efficacy while maintaining a favorable risk/benefit profile.